News
Press Releases
2016/08/01
WuXi AppTec’s Research Service Division Collaborates with Pelago Bioscience to Provide CETSA® based Target Engagement Assays
Stockholm, Münich, Shanghai, August 1, 2016 –WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its Research Service Division(RSD) will collaborate with Pelago Bioscience, a Swedish biotech company to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA ®)method.
Read more2016/05/12
WuXi AppTec’s Pharmaceutical Development Service and Analytical Service Passes EMA Inspection
Shanghai, May 12– WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its pharmaceutical facilities and analytical and stability testing facilities in Shanghai passed the European Medicines Agency (EMA)inspection for GMP compliance, with “no critical and no major findings.” This is the third consecutive time WuXi has passed the EMA inspection.
Read more2016/04/15
WuXi AppTec Acquires Crelux
Munich, Germany, April 15, 2016-WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich, Germany. The addition of Crelux provides augmented scientific depth and complements existing capabilities within the WuXi structure-based drug discovery platform.
Read more2016/04/11
WuXi AppTec Lab Testing Division’s Analytical and Stability Testing Facilities Passed FDA Inspection
Shanghai, April 11, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that WuXi Lab Testing Division (LTD)’s late-and commercial-stage analytical and stability testing facilities in Shanghai successfully passed an FDA inspection for GMP compliance.
Read more2016/04/08
Juno Therapeutics and WuXi AppTec Announce New Company to Develop Novel Cell-Based Cancer Immunotherapies in China
SEATTLE and SHANGHAI– April 8, 2016 – Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that they have started a new company in China.
Read more